Esmeralda Bosman

Utrecht University NL

0000-0003-1314-4065

Publications

101

Citations

H-Index

i10-Index

2.5

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Lipopeptide-mediated delivery of CRISPR/Cas9 ribonucleoprotein complexes for gene editing and correction.

Mert Öktem, T. Nguyen, E. Bosman, Marcel H A M Fens, Massimiliano Caiazzo - Journal of Controlled Release, 2025

Cited by 4 Semantic Scholar

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

Danny Wilbie, Selma Eising, V. Amo-Addae, Johanna Walther, E. Bosman - bioRxiv, 2023

Cited by 2 Semantic Scholar

Research Topics

Advanced biosensing and bioanalysis techniques (4) CRISPR and Genetic Engineering (4) RNA Interference and Gene Delivery (3) Nanoparticle-Based Drug Delivery (2) Extracellular vesicles in disease (2)

Affiliations

Utrecht University

NL 2025 - 2012

Pharmo Institute

NL 2025 - 2025

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Esmeralda Bosman

Publication & Citation Trends

Publications

Lipopeptide-mediated delivery of CRISPR/Cas9 ribonucleoprotein complexes for gene editing and correction.

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back